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Abstract
Background: Toll-like receptor 2 (TLR2) represents a reasonable functional and positional candidate gene for
Alzheimer’s disease (AD) as it is located under the linkage region of AD on chromosome 4q, and functionally is
involved in the microglia-mediated inflammatory response and amyloid-b clearance. The -196 to -174 del
polymorphism affects the TLR2 gene and alters its promoter activity.
Methods: We recruited 800 unrelated Northern Han Chinese individuals comprising 400 late-onset AD (LOAD)
patients and 400 healthy controls matched for gender and age. The -196 to -174 del polymorphism in the TLR2
gene was genotyped using the polymerase chain reaction (PCR) method.
Results: There were significant differences in genotype (P = 0.026) and allele (P = 0.009) frequencies of the -196 to
-174 del polymorphism between LOAD patients and controls. The del allele was associated with an increased risk
of LOAD (OR = 1.31, 95% CI = 1.07-1.60, Power = 84.9%). When these data were stratified by apolipoprotein E
(ApoE) ε4 status, the observed association was confined to ApoE ε4 non-carriers. Logistic regression analysis
suggested an association of LOAD with the polymorphism in a recessive model (OR = 1.64, 95% CI = 1.13-2.39,
Bonferroni corrected P = 0.03).
Conclusions: Our data suggest that the -196 to -174 del/del genotype of TLR2 may increase risk of LOAD in a
Northern Han Chinese population.
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Background
Toll-like receptor 2 (TLR2) represents a reasonable
functional and positional candidate gene for Alzheimer’s
disease (AD) as it is located under the linkage region of
AD on chromosome 4q [1], and is functionally involved
in the microglia-mediated inflammatory response and
amyloid b (Ab) clearance [2-6]. Genetic studies on the
TLR2 gene have identified a number of polymorphisms
which have been shown to affect host defense, disease
progression and be linked to differential disease suscept-
ibilities [7]. We have assessed the involvement of 7 sin-
gle nucleotide polymorphisms (SNPs) (Arg 677Trp,
Arg753Gln, rs1898830, rs11938228, rs3804099,
rs3804100, and rs7656411) as well as a short tandem
GT repeat polymorphism in intron 2 of the TLR2 gene
in the risk of developing late-onset AD (LOAD) [8,9],
and found an association of GT repeat polymorphism
with an increased risk for LOAD in our previous stu-
dies. A 22-bp nucleotide deletion at position -196 to
-174 of the untranslated 5’-region in TLR2 gene is asso-
ciated with reduced transcriptional activity compared to
the wild type allele in luciferase reporter assays [10].
This polymorphism has already been shown to be asso-
ciated with an increased risk of noncardiac gastric can-
cer, susceptibility to cervical cancer, hepatitis C viral
loads and susceptibility to hepatocellular carcinoma
[11-13]. In light of the important role that TLR2 plays
with respect to the immune response in the pathogen-
esis of AD [2-6], we hypothesized that the -196 to -174
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Our study was comprised of 400 sporadic LOAD cases
(189 female and 211 male; age > 65 years; mean age =
82.8 ± 7.1 years; age at onset = 75.4 ± 5.9 years) and
400 healthy controls subjects matched for sex and age
(189 female and 211 male; mean age = 81.4 ± 5.4 years).
All participants originated from Northern Han Chinese
populations. A clinical diagnosis of probable AD was
established according to the criteria of National Institute
of Neurological and Communicative Disorders and
Stroke and the Alzheimer’s disease and Related Disor-
ders Association (NINCDS-ADRDA) [14]. All AD cases
were defined as sporadic because family histories
showed no mention of first-degree relatives with demen-
tia. Control subjects were unrelated individuals selected
from the Health Examination Center of the Qingdao
Municipal Hospital. These subjects were confirmed
healthy and neurologically normal by complete neurolo-
gical and medical examinations comprised of medical
history and laboratory examinations. Written informed
consent was obtained from all individuals and the study
was approved by the Institute Ethical Committee.
Genotyping
Genomic DNA was extracted from peripheral blood leu-
kocytes using the standard method [15]. Polymorphisms
at TLR2 -196 to -174del were investigated using the
polymerase chain reaction (PCR) method, following the
procedures described by Tahara et al [11]. The apolipo-
protein E (ApoE) genotype was determined according to
the method described by Donohoe et al [16]. Two inves-
tigators independently reviewed all results.
Statistical analysis
Hardy-Weinberg equilibrium was assessed using the
Chi-square test. Genotype and allele distributions were
compared using the Chi-square test. Differences in
allele and genotype distribution between cases and
controls were analyzed using logistic regression
adjusted for age and ApoE ε4 status under various
genetic models. The Wald P value was multiplied by 3
as a Bonferroni adjustment for the 3 genetic models
tested. The P value, odds ratios (OR) and 95% confi-
dence intervals (CI) were calculated. Estimation of the
statistical power was performed with the STPLAN 4.3
software. Data were analyzed using a commercially
available statistical package (SPSS Version 13.0, SPSS
Inc., Chicago, IL). The criterion used for significant
differences is P < 0.05.
Results
The alleles and genotypes frequencies of LOAD patients
and controls in the total sample and after stratification for
ApoE ε4 allele are given in Table 1. The distribution of
genotypes of TLR2 polymorphisms were within the range
of Hardy-Weinberg equilibrium (P = 0.21). There were
significant differences in genotype and allele frequencies
between LOAD and control groups (genotype P = 0.026,
allele P = 0.009). The -196 to -174 del allele significantly
raised the risk of developing LOAD (OR = 1.31, 95%CI =
1.07-1.60, Power = 84.9%). In subjects without ApoE ε4
allele, the allele and genotype distributions between
LOAD patients and controls remain significantly different
(genotype P = 0.027, allele P = 0.009). However, in subjects
with the ApoE ε4 allele, there were no significant differ-
ences. In order to rule out confounding in our crude asso-
ciation analyses, we reevaluated the polymorphism effect
under 3 different models using logistic regression adjust-
ing for age and ApoE ε4 status (Table 2). The -196 to -174
del polymorphism was still found to increase the risk of
LOAD via a recessive model (OR = 1.64, 95% CI = 1.13-
2.39, P = 0.01, Bonferroni corrected P = 0.03).
Discussion
Many experimental and clinical studies have suggested
that TLR2 might play an important role in the
Table 1 Distribution of the TLR2 -196 to -174 del polymorphism in LOAD cases and controls.
N Genotypes n (%) Alleles n (%)
ins/ins del/ins del/del P del ins P
AD 400 150(37.5) 161(40.2) 89(22.2) 0.026 461(57.6) 339(42.4) 0.009
Controls 400 172(43.0) 168(42.0) 60(15.0) 512(64.0) 288(36.0)
ApoEε4(-)
AD 260 94(36.2) 104(40.0) 62(23.8) 0.027 292(56.2) 228(43.8) 0.009
Controls 339 144(42.5) 143(42.2) 52(15.3) 431(63.6) 247(36.4)
ApoEε4(+)
AD 140 56(40.0) 57(40.7) 27(19.3) 0.526 169(60.4) 111(39.6) 0.251
Controls 61 28(45.9) 25(41.0) 8(13.1) 81(66.4) 41(33.6)
ApoE ε4 (+): subjects who carry one or two ε4 alleles; ApoE ε4 (-): subjects who do not carry an ε4 allele.
Yu et al. Journal of Neuroinflammation 2011, 8:136
http://www.jneuroinflammation.com/content/8/1/136
Page 2 of 4
pathogenesis of AD [2-6]. TLR2 is a member of pattern-
recognition receptors in the innate immune system [7].
Increased levels of TLR2 mRNA have been found in
microglia isolated from AD patients [2]. Jana et al. have
supplied several lines of evidence supporting the opinion
that Ab peptides activate microglia via TLR2 as inhibi-
tion of TLR2 through function-blocking antibodies or
siRNA knockdown prevents fibrillar forms of Ab from
inducing nitrite, interleukin-6 (IL-6), or tumor necrosis
factor-alpha (TNF-a) production [3]. Although an
increasing volume of data favors TLR2 -mediated neuro-
toxicity, TLR2 may also be essential for Ab clearance
and in that way provide neuroprotection in AD [4].
Reed-Geaghan et al. reported that CD14, TLR4, and
TLR2 are necessary for binding fibrillar Ab (fAb) to the
cell surface, and are required for phenotypic activation
of microglia and induction of phagocytosis [5]. Richard
et al. demonstrated that TLR2 deficiency in transgenic
AD mice could increase Ab deposition and accelerate
cognitive decline [6].
The -196 to -174 del polymorphism in the TLR2
gene, located on chromosome 4, causes a 22 bp
nucleotide deletion that alters the promoter activity of
TLR2. The TLR2 del/del genotype is reported to show
decreased transactivation of responsive promoters [10].
Consequently, it might be speculated that expression
of TLR2 in microglial cells might exhibit low levels
with the del/del genotype. Further, it can be presumed
that the del/del genotype is more conducive to the
occurrence of AD. Our results suggest a significant
association between the -196 to -174 del allele of TLR2
and the risk of developing LOAD in the Han Chinese
population. Interestingly, this association was restricted
to non-ApoE ε4 carriers, as no association was found
for ApoE ε4 carriers. One possible interpretation is
that the genetic effect of TLR2 is relevant in predispos-
ing to AD only in the absence of the ApoE ε4 allele,
while in ε4 carriers the genetic effect is determined by
this strong susceptibility factor. There is overlap in the
study populations used in present study and in our
previous study [9]. Linkage disequilibrium (LD)
between the GT repeat polymorphism and the -196 to
-174 del polymorphism within the TLR2 gene in the
overlap study population was measured by calculating
the D’ and r2 statistics. These were found to be in
weak linkage disequilibrium (D ’ = 0.376 and r2 =
0.009). Hence, haplotype frequencies were not esti-
mated, and both the GT repeat and the -196 to -174
del polymorphisms might independently influence the
risk of LOAD.
Conclusions
Our data suggest that the -196 to -174 del/del genotype
of TLR2 may increase the risk of LOAD in a Northern
Han Chinese population. Additional independent repli-
cations and functional genetic analyses are warranted to
elucidate the potential mechanisms and the epidemiolo-
gic relevance of these associations.
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